Treatment-resistant PTSD lacks a stable clinical definition across the literature
Posttraumatic stress disorder can remain disabling even after evidence-based care, and the question of when it becomes treatment-resistant PTSD has no single accepted answer. A systematic review of published studies found marked variability in how resistance has been defined, measured, and interpreted, making it difficult to compare therapies or translate findings into day-to-day psychiatric practice.
The review screened 4,046 articles and included 55 studies that either described adult participants with treatment-resistant PTSD or examined non-response to one or more interventions. Across that body of evidence, definitions diverged in ways that went well beyond wording. Some studies centered on medication failure, others on psychosocial non-response, and several on newer approaches such as psychedelic-assisted treatment or emerging interventions. The result is a literature that is rich in experimentation but fragmented in its thresholds for deciding who truly has resistant illness.
One point is difficult to ignore: there is no uniform clinical checkpoint at which PTSD stops being “hard to treat” and becomes resistant.
How the evidence split across pharmacologic, psychosocial, and emerging interventions
The included studies examined several therapeutic categories: pharmacological approaches in 19 studies, psychosocial interventions in 16, psychedelic-assisted treatments in 7, and emerging treatments in 13. That distribution shows how broad the field has become, but it also reveals a structural problem. Each treatment class carries its own assumptions about adequate exposure, response time, and what counts as failure.
For example, a patient who does not improve after a pharmacologic trial may still respond to psychotherapy, while a person with minimal benefit from trauma-focused therapy may later improve with a biologic or experimental approach. PTSD is not a single biological pathway, and that heterogeneity makes resistance harder to define than in disorders with cleaner treatment algorithms. Symptoms can be driven by altered fear processing, sleep disruption, hyperarousal, depressive comorbidity, substance use, dissociation, or repeated trauma exposure, all of which may blunt response to a given intervention without proving the disorder is uniformly resistant.
Some studies in the review reported significant symptom reduction, while others showed mixed or limited efficacy. Those differences are not just academic. They shape whether clinicians see persistent symptoms as a failure of the first treatment, a sign that the wrong modality was chosen, or evidence that the illness itself behaves in a refractory way. Without a consistent framework, the same patient could be labeled a non-responder in one study and partially responsive in another.
Why adherence, delivery, and comorbidity belong in the definition
The review proposes a dynamic reassessment model rather than a fixed binary label. In practical terms, that means treatment resistance should not be assigned solely on the basis of symptom persistence after an arbitrary number of sessions or medication trials. Adherence matters. Treatment delivery matters. Comorbid conditions matter. Mechanism of action matters.
Those elements are clinically decisive because apparent non-response can reflect several different scenarios. A medication may fail because the dose was inadequate, the duration was too short, or the patient could not tolerate the regimen. Psychotherapy may appear ineffective if trauma processing was interrupted, engagement was poor, or another active disorder such as depression or substance use complicated progress. Even when a therapy is delivered exactly as intended, the underlying biology of PTSD may not match the treatment’s mechanism, leaving symptoms unchanged despite proper care.
A rigid label can obscure those distinctions and flatten very different clinical stories into a single category.
The case for biomarkers and clinical subtypes in future criteria
The review also points toward a broader evidence base for future definitions, including biomarkers and clinical subtypes. That direction reflects a biologically plausible need: PTSD likely includes more than one pathophysiologic pattern, and treatment response may differ depending on which pattern dominates. A standardized model built only on symptom scores may miss meaningful variation in stress reactivity, neuroendocrine signaling, inflammatory activity, or other measurable states that influence response.
Incorporating biomarkers would not replace clinical judgment, but it could make resistance criteria more precise. A patient with persistent symptoms and a biologically distinct subtype may require a different intervention strategy than someone whose symptoms persist because treatment was not fully delivered or because a comorbid disorder remained untreated. The same logic applies to psychotherapeutic and emerging biologic approaches: if resistance is defined too narrowly, promising therapies may be discarded too early; if defined too loosely, ineffective treatments may continue to be used without a clear rationale.
The review’s central contribution is methodological as much as clinical. It maps the disorder’s definitional instability and shows why the field has struggled to build a coherent treatment-resistant category for PTSD. That instability affects trial design, enrollment criteria, outcome interpretation, and the bedside conversation about next-step care.
What clinicians and researchers still need from a working TR-PTSD model
A workable definition of treatment-resistant PTSD would need to capture more than symptom persistence. It would need to account for the type of treatment given, whether the treatment was delivered adequately, whether the patient adhered to it, and whether comorbidities interfered with response. It would also need to leave room for treatment mechanism and for measurable clinical or biologic subtypes that may predict who benefits from a particular approach.
Without that structure, research findings will remain difficult to compare, and clinicians will continue to make decisions using thresholds that vary from study to study. The review makes clear that the field has reached a point where better naming is not a semantic exercise; it is a prerequisite for better trials, better stratification, and more credible treatment selection.
A standardized definition still does not exist, and the next step will be deciding which response measures deserve to anchor it.